A META-ANALYSIS OF PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME TREATMENT IN CANCER PATIENTS WITH FEBRILE NEUTROPENIA

被引:0
|
作者
Zhang Weidong [1 ]
Xiao Chun [2 ]
Zhou Sixin [3 ]
Wang Rui [1 ]
Wang Li [1 ]
Jia Liping [1 ]
Ma Jinqiu [1 ]
Wang Na [1 ]
机构
[1] First Hosp Qinhuangdao, Qinhuangdao 066000, Peoples R China
[2] PLA Rocket Force, Gen Hosp, Dept Gen Surg, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China
来源
BIOSCIENCE JOURNAL | 2016年 / 32卷 / 06期
关键词
Meta-analysis; Piperacillin/Tazobactam; Cefepime; Febrile neutropenia; Cancer; STEM-CELL TRANSPLANTATION; EMPIRICAL-TREATMENT; OPEN-LABEL; MONOTHERAPY; TAZOBACTAM; MULTICENTER; MANAGEMENT; THERAPY; FEVER; CHEMOTHERAPY;
D O I
暂无
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Febrile neutropenia (FN) causes a major threat to cancer patients after chemotherapy. Broad-spectrum antibiotic treatment is a well-established practice for febrile neutropenia. Piperacillin/Tazobactam (P/T) is the frequently used antibiotic in most of FN cases, whereas the use of cefepime remains unclear regarding its potential risk. However, little systematic analysis has been conducted about comparison between these two drugs. Thus, we undertook this meta-analysis to compare these two monotherapies for febrile neutropenia. Through searching Pubmed, Google scholar, Medline databases, EMBASE, OvidSP, ScienceDirect, Web of science, and China Journal Net (CJN) databases, we used the keywords "(Piperacillin/Tazobactam AND cefepime) AND (febrile neutropenia) AND (cancer or tumor)". Only studies with randomized controlled trials were included in the meta-analysis. We screened out a total number of seven clinical trials. This meta-analysis supported that P/T treatment was superior to cefepime treatment based on the average OR comparison, without statistical significance (OR = 1.27, 95% confidence interval = 0.98 to 1.64, p = 0.07). We further divided the seven studies into two subgroups based on age and treatment time. The young group (age <= 19) showed no significant difference (OR = 1.10, p = 0.65). While the old group (age > 19) showed that P/T treatment was better than cefepime with statistical difference (OR = 1.44, p = 0.05). The short-term group (time <= 3 ds) showed P/T treatment was better than cefepime with statistical difference (OR = 1.40, p = 0.05). While in the long-term group (time > 5 ds), there was no significant difference between P/T and cefepime therapy (OR = 1.06, p = 0.79) Asymmetry in Funnel plots indicated no publication bias (CHI2 = 1.47, I-2 = 0%, and p-value = 0.96) in this meta-analysis. It would be a good clinical trial to use P/T treatment to cure FN in cancer patients compared with cefepime treatment, especially in adult patients or patients with a short-term treatment period. This meta-analysis is practically important during antibiotic treatment in FN management.
引用
收藏
页码:1669 / 1678
页数:10
相关论文
共 50 条
  • [1] Piperacillin/Tazobactam Versus Cefozopran for the Empirical Treatment of Pediatric Cancer Patients With Febrile Neutropenia
    Ichikawa, Mizuho
    Suzuki, Daisuke
    Ohshima, Junjiro
    Cho, Yuko
    Kaneda, Makoto
    Iguchi, Akihiro
    Ariga, Tadashi
    PEDIATRIC BLOOD & CANCER, 2011, 57 (07) : 1159 - 1162
  • [2] Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: A randomized comparison
    Corapcioglu, F
    Sarper, N
    Zengin, E
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2006, 23 (03) : 177 - 186
  • [3] Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan
    Tamura, Kazuo
    Akiyama, Nobu
    Kanda, Yoshinobu
    Saito, Masahiro
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2015, 21 (09) : 654 - 662
  • [4] Piperacillin/Tazobactam Versus Cefepime for the Empirical Treatment of Pediatric Cancer Patients With Neutropenia and Fever: A Randomized and Open-Label Study
    Uygun, Vedat
    Karasu, Gulsun Tezcan
    Ogunc, Dilara
    Yesilipek, Akif
    Hazar, Volkan
    PEDIATRIC BLOOD & CANCER, 2009, 53 (04) : 610 - 614
  • [5] Randomized Trial of Cefozopran Versus Cefepime as Empirical Antibiotic Treatment of Febrile Neutropenia in Pediatric Cancer Patients
    Sarashina, Takeo
    Kobayashi, Ryoji
    Yoshida, Makoto
    Toriumi, Naohisa
    Suzuki, Daisuke
    Sano, Hirozumi
    Azuma, Hiroshi
    PEDIATRIC BLOOD & CANCER, 2014, 61 (11) : 1992 - 1995
  • [6] A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India
    Aamir, Mohammad
    Abrol, Pankaj
    Sharma, Deepak
    Punia, Harish
    TROPICAL DOCTOR, 2016, 46 (03) : 142 - 148
  • [7] Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy - a real-life experience
    Karim, Najmul
    Kabir, Alamgir
    Islam, Manirul
    Biswas, Akhil Ranjan
    Wasim, Mohammed
    Alam, Mahbubul
    Chowdhury, Nobendu
    Islam, Mohammed Nadimul
    Tabassum, Tamanna
    Hasan, Mohammad Jahid
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2022, 34 (01)
  • [8] Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia
    Karaman, Serap
    Vural, Sema
    Yildirmak, Yildiz
    Emecen, Merve
    Erdem, Ela
    Kebudi, Rejin
    PEDIATRIC BLOOD & CANCER, 2012, 58 (04) : 579 - 583
  • [9] Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia
    Vural, Sema
    Erdem, Ela
    Gulec, Seda Geylani
    Yildirmak, Yildiz
    Kebudi, Rejin
    PEDIATRICS INTERNATIONAL, 2010, 52 (02) : 262 - 267
  • [10] PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA
    Solorzano-Santos, Fortino
    Quezada-Herrera, Anai
    Fuentes-Pacheco, Yazmin
    Rodriguez-Coello, Genoveva
    Aguirre-Morales, Carlos E.
    Izelo-Flores, Dassaev
    Munoz-Hernandez, Onofre
    Miranda-Novales, Maria G.
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2019, 71 (04): : 283 - 290